Breaking News Instant updates and real-time market news.

AMGN

Amgen

$167.24

-0.31 (-0.19%)

16:12
10/05/16
10/05
16:12
10/05/16
16:12

Amgen to present new data on IMLYGIC, Vectibix at ESMO

Amgen announced that new data on IMLYGIC in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix will be presented at the European Society for Medical Oncology 2016 Congress, Oct. 7-11, 2016, in Copenhagen. IMLYGIC presentations include interim results from a Phase 2 trial evaluating IMLYGIC in combination with ipilimumab versus ipilimumab alone in patients with unresected stage IIIB-IV melanoma. Vectibix abstracts include retrospective analyses of the first-line Phase 3 PRIME and PEAK studies, evaluating the association between tumor site of origin and treatment efficacy in patients with RAS wild-type metastatic colorectal cancer.

  • 07

    Oct

  • 07

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$167.24

-0.31 (-0.19%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

HMST

HomeStreet

$31.85

2.5 (8.52%)

, UMBF

UMB Financial

$79.36

2.36 (3.06%)

14:55
12/06/16
12/06
14:55
12/06/16
14:55
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$31.85

2.5 (8.52%)

UMBF

UMB Financial

$79.36

2.36 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

UMBF

UMB Financial

$79.36

2.36 (3.06%)

, IM

Ingram Micro

14:55
12/06/16
12/06
14:55
12/06/16
14:55
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$79.36

2.36 (3.06%)

IM

Ingram Micro

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

GMED

Globus Medical

$23.25

0.235 (1.02%)

, TLN

Taken private

14:55
12/06/16
12/06
14:55
12/06/16
14:55
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$23.25

0.235 (1.02%)

TLN

Taken private

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONC

Sonic

$25.47

-0.02 (-0.08%)

14:52
12/06/16
12/06
14:52
12/06/16
14:52
Conference/Events
Sonic management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

, S

Sprint

$8.25

0.195 (2.42%)

14:50
12/06/16
12/06
14:50
12/06/16
14:50
Periodicals
Breaking Periodicals news story on SoftBank, Sprint, T-Mobile »

SoftBank's Son…

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

S

Sprint

$8.25

0.195 (2.42%)

TMUS

T-Mobile

$55.02

0.58 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Dec

  • 04

    Jan

CRHM

CRH Medical

$5.45

-0.2 (-3.54%)

14:50
12/06/16
12/06
14:50
12/06/16
14:50
Conference/Events
CRH Medical management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PLAY

Dave & Buster's

$48.83

1.29 (2.71%)

14:49
12/06/16
12/06
14:49
12/06/16
14:49
Options
Dave & Buster's options imply 9.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 09

    Jan

  • 09

    Jan

RHHBY

Roche

$27.67

0.47 (1.73%)

14:46
12/06/16
12/06
14:46
12/06/16
14:46
Hot Stocks
Genentech says FDA approves Avastin for treatment of type of ovarian cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

14:46
12/06/16
12/06
14:46
12/06/16
14:46
Hot Stocks
YouTube says paid out over $1B to music industry in past year »

Alphabet's (GOOG)…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

SNE

Sony

$28.19

0.045 (0.16%)

VIVHY

Vivendi

$18.98

0.225 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

S

Sprint

$8.22

0.17 (2.11%)

14:45
12/06/16
12/06
14:45
12/06/16
14:45
Options
Sprint call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 04

    Jan

PBIB

Porter Bancorp

$2.03

-0.44 (-17.81%)

14:44
12/06/16
12/06
14:44
12/06/16
14:44
Hot Stocks
Breaking Hot Stocks news story on Porter Bancorp »

Seidman reports 9.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$77.24

0.53 (0.69%)

, CAKE

Cheesecake Factory

$61.40

0.92 (1.52%)

14:37
12/06/16
12/06
14:37
12/06/16
14:37
Hot Stocks
NPD says Q3 foodservice visits fall 1%, quick service restaurant traffic drops »

Market researcher NPD…

DRI

Darden

$77.24

0.53 (0.69%)

CAKE

Cheesecake Factory

$61.40

0.92 (1.52%)

CMG

Chipotle

$368.42

-27.8522 (-7.03%)

YUM

Yum! Brands

$63.41

0.35 (0.56%)

PNRA

Panera Bread

$213.51

-0.16 (-0.07%)

JACK

Jack in the Box

$108.24

1.09 (1.02%)

MCD

McDonald's

$119.04

-0.25 (-0.21%)

DPZ

Domino's Pizza

$167.99

1.7 (1.02%)

QSR

Restaurant Brands

$48.14

0.05 (0.10%)

WEN

Wendy's

$12.85

0.23 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 20

    Dec

  • 09

    Jan

VRA

Vera Bradley

$14.74

0.67 (4.76%)

14:32
12/06/16
12/06
14:32
12/06/16
14:32
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PLAY

Dave & Buster's

$48.83

1.29 (2.71%)

, AVAV

AeroVironment

$28.58

0.58 (2.07%)

14:31
12/06/16
12/06
14:31
12/06/16
14:31
Earnings
Notable companies reporting after market close »

Notable companies…

PLAY

Dave & Buster's

$48.83

1.29 (2.71%)

AVAV

AeroVironment

$28.58

0.58 (2.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 09

    Jan

HLT

Hilton

$26.31

0.22 (0.84%)

14:25
12/06/16
12/06
14:25
12/06/16
14:25
Options
Hilton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

14:25
12/06/16
12/06
14:25
12/06/16
14:25
General news
Masayoshi Son of Softbank agreed to $50 B investment in the U.S. »

Masayoshi Son of Softbank…

14:20
12/06/16
12/06
14:20
12/06/16
14:20
General news
Treasury Option Action: put buying at the long end »

Treasury Option Action:…

14:18
12/06/16
12/06
14:18
12/06/16
14:18
General news
Averages at best levels of day in afternoon trading »

Stocks have taken a leg…

IL

Intralinks

$13.22

1.95 (17.30%)

14:18
12/06/16
12/06
14:18
12/06/16
14:18
Downgrade
Intralinks rating change  »

Intralinks downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

S

Sprint

$7.96

-0.09 (-1.12%)

, TMUS

T-Mobile

$55.02

0.58 (1.07%)

14:17
12/06/16
12/06
14:17
12/06/16
14:17
Hot Stocks
Breaking Hot Stocks news story on Sprint, T-Mobile, SoftBank »

Sprint, T-Mobile shares…

S

Sprint

$7.96

-0.09 (-1.12%)

TMUS

T-Mobile

$55.02

0.58 (1.07%)

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Dec

  • 04

    Jan

SFTBF

SoftBank

$60.07

-0.15 (-0.25%)

14:16
12/06/16
12/06
14:16
12/06/16
14:16
Hot Stocks
Trump says SoftBank has agreed to invest $50B in U.S. »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
12/06/16
12/06
14:16
12/06/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/06/16
12/06
14:16
12/06/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BF.B

Brown Forman, also tag with BFA, BFB

$44.91

-0.17 (-0.38%)

, BFB

Brown-Forman, also tag with BF.A, BF.B

14:14
12/06/16
12/06
14:14
12/06/16
14:14
Technical Analysis
Brown-Forman technical notes ahead of earnings news »

The shares have just…

BF.B

Brown Forman, also tag with BFA, BFB

$44.91

-0.17 (-0.38%)

BFB

Brown-Forman, also tag with BF.A, BF.B

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ALK

Alaska Air

$83.91

0.79 (0.95%)

, VA

Virgin America

$56.45

-0.1 (-0.18%)

14:10
12/06/16
12/06
14:10
12/06/16
14:10
Hot Stocks
Breaking Hot Stocks news story on Alaska Air, Virgin America »

Alaska Air 'remains…

ALK

Alaska Air

$83.91

0.79 (0.95%)

VA

Virgin America

$56.45

-0.1 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.